Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq.
Arch Razi Inst. 2022 Feb 28;77(1):199-204. doi: 10.22092/ARI.2021.356535.1862. eCollection 2022 Feb.
Pregnancy termination for a variety of fetal or maternal conditions has been defined as one of the common obstetrical procedures. The presence of an earlier uterine scar has been found as a highly significant risk factor, which needs to be considered before the election of the misoprostol for the termination of pregnancy (TOP) uses. This study aimed to evaluate the safety of vaginal misoprostol in patients who had an earlier uterine scar, and whether its utilization might result in increasing the risks of uterine ruptures. In total, 250 participants were included in the experimental model and divided into two groups including 95 patients in their 2 trimester of pregnancy with confirmed non-viable fetus and scarred uterus (study group) and 155 pregnant women with no scar in their uterus and missed miscarriage (control group). They received misoprostol tablets in accordance with the Security Hospital Protocol for the TOP. The safety has been specified according to the number of women that had full abortions with no complications. The study group with uterine scar included 95 cases that comprised 38% of the total participants in the study (n=250). Out of 95 cases, 64 (67.3%) patients had successful abortions completely, compared to the control group (the patients with no scar), 111 (71.6%) of whom had complete abortions (<0.001). However, 44 (28.4%) and 31 (32.6%) patients in the control and study groups, respectively, were in need of surgical evacuations either for the incomplete conception product expulsion or as a result of the excessive per-vaginal bleeding. The use of the misoprostol for the TOP has not been contra-indicated in the females who had Caesarean scars. Moreover, it is efficient in females who do not have scarred uterus.
因各种胎儿或母体状况而终止妊娠已被定义为常见的产科程序之一。先前的子宫瘢痕已被发现是一个高度显著的危险因素,在选择米索前列醇终止妊娠(TOP)之前需要考虑这一因素。本研究旨在评估阴道给予米索前列醇在有先前子宫瘢痕的患者中的安全性,以及其使用是否会增加子宫破裂的风险。共有 250 名参与者被纳入实验模型,并分为两组,包括 95 名妊娠中期(妊娠 2 期)且确诊为无生机胎儿和有瘢痕子宫的患者(研究组)和 155 名无子宫瘢痕且有稽留流产的孕妇(对照组)。他们根据安全医院 TOP 协议接受米索前列醇片。安全性根据无并发症完全流产的妇女人数来指定。有子宫瘢痕的研究组包括 95 例,占研究总人数的 38%(n=250)。在 95 例中,有 64 例(67.3%)患者完全流产成功,而对照组(无瘢痕的患者)中有 111 例(71.6%)完全流产(<0.001)。然而,对照组(有瘢痕的患者)中分别有 44(28.4%)和 31(32.6%)例患者需要进行手术清除,原因是不完全的妊娠产物排出或因阴道出血过多。对于有剖宫产瘢痕的女性,米索前列醇用于 TOP 并不被禁止。此外,它对没有瘢痕子宫的女性也有效。